Expires on: 03/05/2024
Description
Embark on a transformative journey in cancer treatment research with the PhD opportunity in “Protein-based Chelators for Targeted Radionuclide Therapy.” This project, commencing March 5th, 2024, explores innovative approaches to enhance the development of radiopharmaceuticals for targeted cancer treatment. As a prospective candidate, you have the chance to contribute to groundbreaking advancements in cancer therapy by integrating protein-based alternatives into the production process, providing new possibilities for targeted radionuclide therapy.
The PhD project aims to enhance the development of radiopharmaceuticals by implementing and benchmarking protein-based alternatives to conventional synthetic chemical chelators. These protein-based alternatives will be directly fused to proteinous carriers, such as peptides or nanobodies, produced recombinantly, and rigorously benchmarked. The research provides a platform for innovation and exploration in targeted radionuclide therapy.
Eligibility:
Prospective candidates must hold a Master of Sciences degree with a background in Biology, (Bio)chemistry, or Bio-engineering. The project welcomes individuals with a passion for advancing cancer treatment and exploring novel approaches in the field.
Documents:
Before applying, candidates are advised to consult the guidelines for the application. Specific document requirements will be detailed in the application guidelines.